EMA Application withdrawn: Zektayos - Hepjuvo (obeticholic acid) — Advanz Pharma Limited

View source ↗

Summary

The EMA has withdrawn the application for Zektayos - Hepjuvo (obeticholic acid) by Advanz Pharma Limited for fatty liver disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fatty Liver Disease

Drugs mentioned

• Zektayos - Hepjuvo (obeticholic acid)

Snippet

Status: Application withdrawn. Therapeutic area: Fatty Liver. MAH: Advanz Pharma Limited